<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39363220</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2661-801X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>BMC chemistry</Title><ISOAbbreviation>BMC Chem</ISOAbbreviation></Journal><ArticleTitle>SMILES-based QSAR virtual screening to identify potential therapeutics for COVID-19 by targeting 3CL<sup>pro</sup> and RdRp viral proteins.</ArticleTitle><Pagination><StartPage>191</StartPage><MedlinePgn>191</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">191</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13065-024-01302-3</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has prompted the medical systems of many countries to develop effective treatments to combat the high rate of infection and death caused by the disease. Within the array of proteins found in SARS-CoV-2, the 3 chymotrypsin-like protease (3CL<sup>pro</sup>) holds significance as it plays a crucial role in cleaving polyprotein peptides into distinct functional nonstructural proteins. Meanwhile, RNA-dependent RNA polymerase (RdRp) takes center stage as the key enzyme tasked with replicating the viral genomic RNA within host cells. These proteins, 3CL<sup>pro</sup> and RdRp, are deemed optimal subjects for QSAR modeling due to their pivotal functions in the viral lifecycle. In this study, SMILES-based QSAR classification models were developed for a dataset of 2377 compounds that were defined as either active or inactive against 3CLpro and RdRp. Pharmacophore (PH4) and QSAR modeling were used for the virtual screening on 60.2 million compounds including ZINC, ChEMBL, Molport, and MCULE databases to identify new potent inhibitors against 3CL<sup>pro</sup> and RdRp. Then, a filter was established based on typical molecular characteristics to identify drug-like molecules. The molecular docking was also performed to evaluate the binding affinity of 156 AND 51 potential inhibitors to 3CL<sup>pro</sup> and RdRp, respectively. Among the 15 hits identified based on molecular docking scores, M3, N2, and N4 were identified as promising inhibitors due to their good synthetic accessibility scores (3.07, 3.11, and 3.29 out of 10 for M3, N2, and N4 respectively). These compounds contain amine functional groups, which are known for their crucial role in the binding interactions between drugs and their targets. Consequently, these hits have been chosen for further biological assay studies to validate their activity. They may represent novel 3CL<sup>pro</sup> and RdRp inhibitors possessing drug-like properties suitable for COVID-19 therapy.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bazzi-Allahri</LastName><ForeName>Faezeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Zabol, Zabol, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiri</LastName><ForeName>Fereshteh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Zabol, Zabol, Iran. fereshteh.shiri@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadi</LastName><ForeName>Shahin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Pharmaceutical Chemistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toropova</LastName><ForeName>Alla P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toropov</LastName><ForeName>Andrey A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>BMC Chem</MedlineTA><NlmUniqueID>101741142</NlmUniqueID><ISSNLinking>2661-801X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3CLpro and RdRp</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Molecular docking</Keyword><Keyword MajorTopicYN="N">SMILES-based QSAR classification</Keyword><Keyword MajorTopicYN="N">Virtual screening</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>23</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39363220</ArticleId><ArticleId IdType="pmc">PMC11451266</ArticleId><ArticleId IdType="doi">10.1186/s13065-024-01302-3</ArticleId><ArticleId IdType="pii">10.1186/s13065-024-01302-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li J, Wang J, Wang H. Emerging landscape of preclinical models for studying COVID-19 neurologic diseases. ACS Pharmacol Transl Sci. 2023;6(10):1323–39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10580392</ArticleId><ArticleId IdType="pubmed">37854617</ArticleId></ArticleIdList></Reference><Reference><Citation>Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. Nat Microbiol. 2019;4(4):565–77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30833727</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W, Jochmans D, Xie H, Yang H, Li J, Su H, Chang D, Wang J, Peng J, Zhu L. Design, synthesis, and biological evaluation of peptidomimetic aldehydes as broad-spectrum inhibitors against enterovirus and SARS-CoV-2. J Med Chem. 2021;65(4):2794–808.</Citation><ArticleIdList><ArticleId IdType="pubmed">33872498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020;10(5):766–88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102550</ArticleId><ArticleId IdType="pubmed">32292689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneller DW, Phillips G, O’Neill HM, Jedrzejczak R, Stols L, Langan P, Joachimiak A, Coates L, Kovalevsky A. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat Commun. 2020;11(1):3202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314768</ArticleId><ArticleId IdType="pubmed">32581217</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, Wang T, Sun Q, Ming Z, Zhang L. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368(6492):779–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164392</ArticleId><ArticleId IdType="pubmed">32277040</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue H, Li J, Xie H, Wang Y. Review of drug repositioning approaches and resources. Int J Biol Sci. 2018;14(10):1232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097480</ArticleId><ArticleId IdType="pubmed">30123072</ArticleId></ArticleIdList></Reference><Reference><Citation>Leelananda SP, Lindert S. Computational methods in drug discovery. Beilstein J Org Chem. 2016;12(1):2694–718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5238551</ArticleId><ArticleId IdType="pubmed">28144341</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung I. Lopinavir/ritonavir, ribavirin and IFN-beta combination for nCoV treatment. NCT04276688. 2020.</Citation></Reference><Reference><Citation>USNLo M. A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19. ClinicalTrialsgov. 2020.</Citation></Reference><Reference><Citation>Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190303</ArticleId><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo R, Hernán M. Randomized clinical trial for the prevention of SARS-CoV-2 infection (COVID-19) in healthcare personnel (EPICOS). ClinicalTrials. gov; 2020.</Citation></Reference><Reference><Citation>Wang Z, Xu X. scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, Leydig and Sertoli cells. Cells. 2020;9(4):920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7226809</ArticleId><ArticleId IdType="pubmed">32283711</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer S, Bojkova D, Cinatl J, Van Damme E, Buyck C, Van Loock M, Woodfall B, Ciesek S. Lack of antiviral activity of darunavir against SARS-CoV-2. Int J Infect Dis. 2020;97:7–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7258847</ArticleId><ArticleId IdType="pubmed">32479865</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X-T, Luo Y-L, Xia S-C, Sun Q-F, Ding J-G, Zhou Y, Chen W, Wang X-F, Zhang W-W, Du W-J. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020;24(6):3390–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32271456</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YW, Yiu CPB, Wong K-Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research. 2020;9:129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7062204</ArticleId><ArticleId IdType="pubmed">32194944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabirotchkin S, Peluffo AE, Bouaziz J, Cohen D. Focusing on the unfolded protein response and autophagy related pathways to reposition common approved drugs against COVID-19. Basel: MDPI AG; 2020.</Citation></Reference><Reference><Citation>Verdugo-Paiva F, Izcovich A, Ragusa M, Rada G. C.-L.-OW Group, Lopinavir/ritonavir for the treatment of COVID-19: a living systematic review protocol. medRxiv. 2020;9:399.</Citation><ArticleIdList><ArticleId IdType="pubmed">32678815</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A, Hershan AA, Kamal MA, Helmi N. Therapeutic management of patients with COVID-19: a systematic review. Infect Prevent Pract. 2020;2(3):100061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7162768</ArticleId><ArticleId IdType="pubmed">34316558</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatansever S, Schlessinger A, Wacker D, Kaniskan HÜ, Jin J, Zhou MM, Zhang B. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: state-of-the-arts and future directions. Med Res Rev. 2021;41(3):1427–73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043990</ArticleId><ArticleId IdType="pubmed">33295676</ArticleId></ArticleIdList></Reference><Reference><Citation>Prachayasittikul V, Worachartcheewan A, Toropova A, Toropov A, Schaduangrat N, Prachayasittikul V, Nantasenamat C. Large-scale classification of P-glycoprotein inhibitors using SMILES-based descriptors. SAR QSAR Environ Res. 2017;28(1):1–16.</Citation><ArticleIdList><ArticleId IdType="pubmed">28056566</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsou LK, Yeh S-H, Ueng S-H, Chang C-P, Song J-S, Wu M-H, Chang H-F, Chen S-R, Shih C, Chen C-T. Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery. Sci Rep. 2020;10(1):16771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545175</ArticleId><ArticleId IdType="pubmed">33033310</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Y-C, Rensi SE, Torng W, Altman RB. Machine learning in chemoinformatics and drug discovery. Drug Discov Today. 2018;23(8):1538–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6078794</ArticleId><ArticleId IdType="pubmed">29750902</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiri F, Pirhadi S, Rahmani A. Identification of new potential HIV-1 reverse transcriptase inhibitors by QSAR modeling and structure-based virtual screening. J Recept Signal Transduct. 2018;38(1):37–47.</Citation><ArticleIdList><ArticleId IdType="pubmed">29254400</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelli CI, Toropov AA, Toropova AP, Benfenati E. Ecosystem ecology: Models for acute toxicity of pesticides towards Daphnia magna. Environ Toxicol Pharmacol. 2020;80:103459.</Citation><ArticleIdList><ArticleId IdType="pubmed">32721590</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotfi S, Ahmadi S, Zohrabi P. QSAR modeling of toxicities of ionic liquids toward Staphylococcus aureus using SMILES and graph invariants. Struct Chem. 2020;31:2257–70.</Citation></Reference><Reference><Citation>Manganelli S, Benfenati E, Manganaro A, Kulkarni S, Barton-Maclaren TS, Honma M. New quantitative structure–activity relationship models improve predictability of Ames mutagenicity for aromatic azo compounds. Toxicol Sci. 2016;153(2):316–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">27413112</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov J, Polshakov D, Kato-Weinstein J, Zhou Q, Li Y, Granet R, Garner L, Deng Y, Liu C, Albaiu D. Quantitative structure–activity relationship machine learning models and their applications for identifying viral 3CLpro-and RdRp-targeting compounds as potential therapeutics for COVID-19 and related viral infections. ACS Omega. 2020;5(42):27344–58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571315</ArticleId><ArticleId IdType="pubmed">33134697</ArticleId></ArticleIdList></Reference><Reference><Citation>Toropov A, Toropova A, Benfenati E, Gini G, Leszczynska D, Leszczynski J. CORAL: classification model for predictions of anti-sarcoma activity. Curr Top Med Chem. 2012;12(24):2741–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">23368100</ArticleId></ArticleIdList></Reference><Reference><Citation>Toropov AA, Toropova AP, Rasulev BF, Benfenati E, Gini G, Leszczynska D, Leszczynski J. CORAL: binary classifications (active/inactive) for liver-related adverse effects of drugs. Curr Drug Saf. 2012;7(4):257–61.</Citation><ArticleIdList><ArticleId IdType="pubmed">23062237</ArticleId></ArticleIdList></Reference><Reference><Citation>Toropova AP, Toropov AA. CORAL: binary classifications (active/inactive) for drug-induced liver injury. Toxicol Lett. 2017;268:51–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28111161</ArticleId></ArticleIdList></Reference><Reference><Citation>Toropova AP, Toropov AA. QSPR and nano-QSPR: what is the difference? J Mol Struct. 2019;1182:141–9.</Citation></Reference><Reference><Citation>Ahmadi S. Mathematical modeling of cytotoxicity of metal oxide nanoparticles using the index of ideality correlation criteria. Chemosphere. 2020;242:125192.</Citation><ArticleIdList><ArticleId IdType="pubmed">31677509</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotfi S, Ahmadi S, Kumar P. A hybrid descriptor based QSPR model to predict the thermal decomposition temperature of imidazolium ionic liquids using Monte Carlo approach. J Mol Liq. 2021;338:116465.</Citation></Reference><Reference><Citation>Kumar A, Kumar P. Cytotoxicity of quantum dots: Use of quasiSMILES in development of reliable models with index of ideality of correlation and the consensus modelling. J Hazard Mater. 2021;402:123777.</Citation><ArticleIdList><ArticleId IdType="pubmed">33254788</ArticleId></ArticleIdList></Reference><Reference><Citation>Soleymani N, Ahmadi S, Shiri F, Almasirad A. QSAR and molecular docking studies of isatin and indole derivatives as SARS 3CLpro inhibitors. BMC Chem. 2023;17(1):32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10079496</ArticleId><ArticleId IdType="pubmed">37024955</ArticleId></ArticleIdList></Reference><Reference><Citation>Toropova AP, Toropov AA, Benfenati E. Semi-correlations as a tool to model for skin sensitization. Food Chem Toxicol. 2021;157:112580.</Citation><ArticleIdList><ArticleId IdType="pubmed">34560179</ArticleId></ArticleIdList></Reference><Reference><Citation>Javidfar M, Ahmadi S. QSAR modelling of larvicidal phytocompounds against Aedes aegypti using index of ideality of correlation. SAR QSAR Environ Res. 2020;31(10):717–39.</Citation><ArticleIdList><ArticleId IdType="pubmed">32930630</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi JB, Shiri F, Pirhadi S, Heidari Z. Discovery of new potential antimalarial compounds using virtual screening of ZINC database. Comb Chem High Throughput Screen. 2015;18(2):227–34.</Citation><ArticleIdList><ArticleId IdType="pubmed">25543686</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunseri J, Koes DR. Pharmit: interactive exploration of chemical space. Nucleic Acids Res. 2016;44(W1):W442–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987880</ArticleId><ArticleId IdType="pubmed">27095195</ArticleId></ArticleIdList></Reference><Reference><Citation>Koes DR, Baumgartner MP, Camacho CJ. Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J Chem Inf Model. 2013;53(8):1893–904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726561</ArticleId><ArticleId IdType="pubmed">23379370</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open babel: an open chemical toolbox. J Cheminform. 2011;3:1–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198950</ArticleId><ArticleId IdType="pubmed">21982300</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemizadeh M, Shiri F, Shahraki S, Razmara Z. A multidisciplinary study for investigating the interaction of an iron complex with bovine liver catalase. Appl Organomet Chem. 2022;36(11): e6881.</Citation></Reference><Reference><Citation>Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5335600</ArticleId><ArticleId IdType="pubmed">28256516</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander T, Freyss J, von Korff M, Rufener C. DataWarrior: an open-source program for chemistry aware data visualization and analysis. J Chem Inf Model. 2015;55(2):460–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">25558886</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntie-Kang F. An in silico evaluation of the ADMET profile of the StreptomeDB database. Springerplus. 2013;2:1–11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736076</ArticleId><ArticleId IdType="pubmed">23961417</ArticleId></ArticleIdList></Reference><Reference><Citation>Newby D, Freitas AA, Ghafourian T. Decision trees to characterise the roles of permeability and solubility on the prediction of oral absorption. Eur J Med Chem. 2015;90:751–65.</Citation><ArticleIdList><ArticleId IdType="pubmed">25528330</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>